La sage décision de l’Inde

NEW YORK – Le rejet par la Cour Suprême de New Delhi de la demande de brevet déposée par le géant pharmaceutique suisse Novartis sur le Glivec, un médicament vedette contre le cancer, est une bonne nouvelle pour les malades indiens atteints d’un cancer. Si d’autres pays en développement suivent l’exemple de l’Inde, ce sera également une bonne nouvelle dans d’autres domaines : plus d’argent pourra être consacré à d’autres besoins, que ce soit la lutte contre le sida, l’éducation ou les investissements destinés à réduire la pauvreté et encourager la croissance.

Mais la décision de la Cour Suprême indienne signifie aussi moins d’argent pour les laboratoires pharmaceutiques multinationaux, qui ont sans surprise réagi de manière excédée en alléguant que ce jugement « allait décourager l'innovation future en Inde », et qu’il constituait un sérieux revers pour la santé publique dans le monde.

Ces affirmations sont largement exagérées. Le jugement de la Cour Suprême indienne fait sens, tant du point de vue économique qu’en termes de politique sociale. Il n’est de plus qu’une tentative locale de rééquilibrer un régime de propriété intellectuelle (PI) qui penche trop en faveur des intérêts pharmaceutiques, au détriment du bien-être social. Il existe en fait un consensus croissant parmi les économistes sur le fait que le régime actuel de PI étouffe en réalité l’innovation.

To continue reading, please log in or enter your email address.

Registration is quick and easy and requires only your email address. If you already have an account with us, please log in. Or subscribe now for unlimited access.

required

Log in

http://prosyn.org/WnZKb5h/fr;
  1. Chris J Ratcliffe/Getty Images

    The Brexit Surrender

    European Union leaders meeting in Brussels have given the go-ahead to talks with Britain on post-Brexit trade relations. But, as European Council President Donald Tusk has said, the most difficult challenge – forging a workable deal that secures broad political support on both sides – still lies ahead.

  2. The Great US Tax Debate

    ROBERT J. BARRO vs. JASON FURMAN & LAWRENCE H. SUMMERS on the impact of the GOP tax  overhaul.


    • Congressional Republicans are finalizing a tax-reform package that will reshape the business environment by lowering the corporate-tax rate and overhauling deductions. 

    • But will the plan's far-reaching changes provide the boost to investment and growth that its backers promise?


    ROBERT J. BARRO | How US Corporate Tax Reform Will Boost Growth

    JASON FURMAN & LAWRENCE H. SUMMERS | Robert Barro's Tax Reform Advocacy: A Response

  3. Murdoch's Last Stand?

    Rupert Murdoch’s sale of 21st Century Fox’s entertainment assets to Disney for $66 billion may mark the end of the media mogul’s career, which will long be remembered for its corrosive effect on democratic discourse on both sides of the Atlantic. 

    From enabling the rise of Donald Trump to hacking the telephone of a murdered British schoolgirl, Murdoch’s media empire has staked its success on stoking populist rage.

  4. Bank of England Leon Neal/Getty Images

    The Dangerous Delusion of Price Stability

    Since the hyperinflation of the 1970s, which central banks were right to combat by whatever means necessary, maintaining positive but low inflation has become a monetary-policy obsession. But, because the world economy has changed dramatically since then, central bankers have started to miss the monetary-policy forest for the trees.

  5. Harvard’s Jeffrey Frankel Measures the GOP’s Tax Plan

    Jeffrey Frankel, a professor at Harvard University’s Kennedy School of Government and a former member of President Bill Clinton’s Council of Economic Advisers, outlines the five criteria he uses to judge the efficacy of tax reform efforts. And in his view, the US Republicans’ most recent offering fails miserably.

  6. A box containing viles of human embryonic Stem Cell cultures Sandy Huffaker/Getty Images

    The Holy Grail of Genetic Engineering

    CRISPR-Cas – a gene-editing technique that is far more precise and efficient than any that has come before it – is poised to change the world. But ensuring that those changes are positive – helping to fight tumors and mosquito-borne illnesses, for example – will require scientists to apply the utmost caution.

  7. The Year Ahead 2018

    The world’s leading thinkers and policymakers examine what’s come apart in the past year, and anticipate what will define the year ahead.

    Order now